Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Yongde LIAO"'
Autor:
Wei Lin, Xiaojun Wang, Mingxin Diao, Yangwei Wang, Rong Zhao, Jiaping Chen, Yongde Liao, Qinghong Long, Yunchong Meng
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background In tumor treatment, protein tyrosine kinase inhibitors (TKIs) have been extensively utilized. However, the efficacy of TKI is significantly compromised by drug resistance. Consequently, finding an effective solution to overcome TK
Externí odkaz:
https://doaj.org/article/bf2f2a9d883c42cb9928acaf3e6eed00
Autor:
Feng Li, Yu Qi, Kuo Li, Zhenwei Shi, Guanchao Ye, Guangyao Wu, Mingliang Wang, Chunyang Zhang, Leonard Wee, Andre Dekker, Chu Han, Zaiyi Liu, Yongde Liao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Objectives Although neoadjuvant immunochemotherapy has been widely applied in non-small cell lung cancer (NSCLC), predicting treatment response remains a challenge. We used pretreatment multimodal CT to explore deep learning-based immunochemotherapy
Externí odkaz:
https://doaj.org/article/cf3f69a414aa48689ba9701e2f9aa827
Autor:
Guanchao Ye, Guangyao Wu, Chunyang Zhang, Mingliang Wang, Hong Liu, Enmin Song, Yuzhou Zhuang, Kuo Li, Yu Qi, Yongde Liao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectivesTo investigate the prediction of pathologic complete response (pCR) in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherapy (NAIC) using quantification of intratumoral heterogeneity from pre-treatment C
Externí odkaz:
https://doaj.org/article/f92556ccf6894c53a2310ea111cf0468
Publikováno v:
Translational Oncology, Vol 44, Iss , Pp 101922- (2024)
Purpose: To evaluate the effectiveness of deep learning radiomics nomogram in distinguishing the occult lymph node metastasis (OLNM) status in clinical stage IA lung adenocarcinoma. Methods: A cohort of 473 cases of lung adenocarcinomas from two hosp
Externí odkaz:
https://doaj.org/article/1b61d114bb834c39885475c04ef9f670
Autor:
Jiaping Chen, Rong Zhao, Yangwei Wang, Han Xiao, Wei Lin, Mingxin Diao, Shiwen He, Peiyuan Mei, Yongde Liao
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-17 (2024)
Abstract Background Lung cancer is the leading cause of cancer-related death worldwide. The sex differences in the occurrence and fatality rates of non-small cell lung cancer (NSCLC), along with its association with estrogen dependence, suggest that
Externí odkaz:
https://doaj.org/article/6f48c0fa2f0043918a3e2d9b2cefc0bf
Autor:
Wangyang Meng, Han Xiao, Rong Zhao, Jiaping Chen, Yangwei Wang, Peiyuan Mei, Hecheng Li, Yongde Liao
Publikováno v:
Cell & Bioscience, Vol 14, Iss 1, Pp 1-19 (2024)
Abstract Background METTL3 plays a significant role as a catalytic enzyme in mediating N6-methyladenosine (m6A) modification, and its importance in tumour progression has been extensively studied in recent years. However, the precise involvement of M
Externí odkaz:
https://doaj.org/article/278b57972c13476a8d2dcf3378232473
Autor:
Yangwei Wang, Tong Yu, Jiaping Chen, Rong Zhao, Mingxin Diao, Peiyuan Mei, Shiwen He, Wenlin Qiu, Guanchao Ye, Lijuan Jiang, Han Xiao, Yongde Liao
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-16 (2023)
Abstract Lung adenocarcinoma (LUAD) is a common type of malignant tumor with poor prognosis and high mortality. In our previous studies, we found that estrogen is an important risk factor for LUAD, and different estrogen statuses can predict differen
Externí odkaz:
https://doaj.org/article/49f10fc0628b42f7a1a5c5cd495bab28
Publikováno v:
Journal of Pharmaceutical Analysis, Vol 13, Iss 6, Pp 625-639 (2023)
In non-small cell lung cancer (NSCLC), the heterogeneity promotes drug resistance, and the restricted expression of programmed death-ligand 1 (PD-L1) limits the immunotherapy benefits. Based on the mechanisms related to translation regulation and the
Externí odkaz:
https://doaj.org/article/35a10b4bd69b4481a552fde285796d9f
Autor:
Minqian Dai, Na Wang, Qin Xia, Yongde Liao, Wei Cao, Jun Fan, Diwei Zhou, Sihua Wang, Xiu Nie
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Neoadjuvant chemoimmunotherapy has demonstrated significant benefit for resectable non-small-cell lung cancer (NSCLC) excluding known EGFR/ALK genetic alterations. Recent evidence has shown that neoadjuvant chemoimmunotherapy could be clinically valu
Externí odkaz:
https://doaj.org/article/5e8a9f4040e24392a7b71cf73b0b9094
Autor:
Kuo Li, Xiaonian Cao, Bo Ai, Han Xiao, Quanfu Huang, Zheng Zhang, Qian Chu, Li Zhang, Xiaofang Dai, Yongde Liao
Publikováno v:
Thoracic Cancer, Vol 12, Iss 15, Pp 2161-2169 (2021)
Abstract Background Advanced non‐small cell lung cancer (NSCLC) accounts for a high proportion of lung cancer cases. Targeted therapy improve the survival in these patients, but acquired drug resistance will inevitably occur. If tumor downstaging i
Externí odkaz:
https://doaj.org/article/6656921c1b754e6f92e474d8f38e0927